A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Completed · Phase 4

Conditions studied: Type 2 Diabetes

In brief

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

Key facts

Study ID

NCT05564039

Run by

Eli Lilly and Company

People needed

282

Starts

2022-11-30

Expected to finish

2024-08-12

Last updated by the study team

2025-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have type 2 diabetes
• Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)
• Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening.
• No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.
• Have had stable body weight (±5%) during the 90 days preceding screening
• Have BMI ≥25 kilogram/square meter (kg/m²)

You may not qualify if…

• Have type 1 diabetes
• Have a history of chronic or acute pancreatitis
• Have a history of
• proliferative diabetic retinopathy, or
• diabetic maculopathy, or
• nonproliferative diabetic retinopathy that requires acute treatment.
• Have any of these cardiovascular (CV) conditions within 60 days prior to screening:
• acute myocardial infarction,
• cerebrovascular accident (stroke), or
• hospitalization due to congestive heart failure (CHF).
• Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF
• Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies
• Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)
• Have been treated with insulin prior to screening
• Exception: use of insulin for gestational diabetes or short-term use (<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
• Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation

Where it is running

• Diabeteszentrum Hamburg West — Hamburg, Germany
• Diseno y Planeacion en Investigacion Medica — Guadalajara, Jalisco, Mexico
• ALL Medical Research, LLC — Cooper City, Florida, United States
• Metabolic Research Institute, Inc. — West Palm Beach, Florida, United States
• NorthShore University Health System — Skokie, Illinois, United States
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa, United States
• Clinvest Research LLC — Springfield, Missouri, United States
• Alliance for Multispecialty Research, LLC — Norman, Oklahoma, United States
• Juno Research — Houston, Texas, United States
• Biopharma Informatic, LLC — Houston, Texas, United States
• Juno Research — Houston, Texas, United States
• Southern Endocrinology Associates — Mesquite, Texas, United States
• North Hills Family Medicine/North Hills Medical Research — North Richland Hills, Texas, United States
• Imelda General Hospital — Bonheiden, Antwerpen, Belgium
• Antwerp University Hospital — Edegem, Antwerpen, Belgium
• ZNA Jan Palfijn — Merksem, Flanders, Belgium
• AZ Nikolaas — Sint-Niklaas, Oost-Vlaanderen, Belgium
• UZ Leuven — Leuven, Vlaams-Brabant, Belgium
• Az Damiaan vzw — Ostend, West-Vlaanderen, Belgium
• InnoDiab Forschung Gmbh — Essen, North Rhine-Westphalia, Germany
• Institut für Diabetesforschung GmbH Münster — Münster, North Rhine-Westphalia, Germany
• Studienzentrum Dr. Tasso Bieler — Riesa, Saxony, Germany
• RED-Institut GmbH — Oldenburg in Holstein, Schleswig-Holstein, Germany
• Medizinisches Versorgungszentrum am Bahnhof Spandau — Spandau, State of Berlin, Germany
• Unidad de Investigación Clínica y Atención Médica HEPA — Guadalajara, Jalisco, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.